4//SEC Filing
Renaud Ronald C JR 4
Accession 0001209191-21-056062
CIK 0001693415other
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 7:32 PM ET
Size
21.1 KB
Accession
0001209191-21-056062
Insider Transaction Report
Form 4
Renaud Ronald C JR
DirectorSee Remarks
Transactions
- Sale
Common Stock
2021-09-14$38.00/sh−409,913$15,576,694→ 0 total(indirect: By Trust) - Sale
Stock Option (right to buy)
2021-09-14−1,071,009→ 0 totalExercise: $7.39Exp: 2027-12-21→ Common Stock (1,071,009 underlying) - Sale
Stock Option (right to buy)
2021-09-14−89,996→ 0 totalExercise: $8.34Exp: 2028-03-06→ Common Stock (89,996 underlying) - Sale
Common Stock
2021-09-14$38.00/sh−503,231$19,122,778→ 0 total - Sale
Common Stock
2021-09-14$38.00/sh−40,909$1,554,542→ 0 total(indirect: By Trust) - Sale
Stock Option (right to buy)
2021-09-14−525,000→ 0 totalExercise: $7.66Exp: 2030-03-02→ Common Stock (525,000 underlying) - Sale
Stock Option (right to buy)
2021-09-14−500,000→ 0 totalExercise: $7.95Exp: 2029-03-07→ Common Stock (500,000 underlying) - Sale
Stcok Option (right to buy)
2021-09-14−325,000→ 0 totalExercise: $23.82Exp: 2031-03-09→ Common Stock (325,000 underlying)
Footnotes (7)
- [F1]As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
- [F2]Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
- [F3]This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.
- [F4]This option was granted on March 3, 2020. This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024.
- [F5]This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 9, 2025.
- [F6]This option was granted on December 22, 2017. The shares underlying became fully vested on March 9, 2021.
- [F7]This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installment through March 7, 2022.
Documents
Issuer
Translate Bio, Inc.
CIK 0001693415
Entity typeother
Related Parties
1- filerCIK 0001354434
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 7:32 PM ET
- Size
- 21.1 KB